Hilts_Craig

Craig Hilts

Hilts_Craig

Craig Hilts

Partner

Boston + 1 617 526 6083

Craig Hilts is a partner in the Corporate Practice Group. His practice focuses on advising domestic and foreign companies in capital markets transactions, corporate governance and public company reporting matters, with a particular emphasis on the life sciences and technology industries. He also frequently represents investment banks in initial public offering and follow-on equity offerings in the life science and technology sectors.

Craig has successfully represented clients in a wide range of complex capital markets transactions, including numerous initial public offerings, follow-on equity offerings, PIPEs, at-the-market offerings, senior debt offerings, convertible debt offerings and liability management transactions.

Craig serves as principal outside counsel for many life science companies in which he provides strategic advice to board of directors and management teams regarding significant transactions, public company obligations and corporate governance. 

Community Activities

Mr. Hilts served on the Business Transactions section of the Boston Bar Association from 2018–2020.

Mr. Hilts serves on the Board of Advisors for Life Science Cares, a national nonprofit organization that brings together companies in the life sciences industry to eliminate the impact of poverty.

Experience

  • Equity Offerings

    • Agios Pharmaceuticals in its $294.1 million follow-on public offering
    • Apellis Pharmaceuticals in its $150 million initial public offering and $1.75 billion in multiple follow-on public offerings
    • Casella Waste Services in multiple follow-on public offerings
    • Constellation Pharmaceuticals in its $60 million initial public offering, $450 million in multiple follow-on public offerings and $65 million private placement
    • Cue Health in its $230 million initial public offering
    • Fulcrum Therapeutics in its $125 million initial public offering, $150 million follow-on public offering and $68.5 million private placement
    • Karyopharm Therapeutics in its $165 million private placement
    • Pandion Therapeutics in its $135 million initial public offering
    • Solid Biosciences in its $125 million follow-on public offering
    • Telix Pharmaceuticals in its direct listing of American depositary shares on the Nasdaq Global Select Market
    • Translate Bio in its $121.6 million initial public offering
    • Verve Therapeutics in its $306 million initial public offering and multiple follow-on public offerings
    • Underwriters in the $655 million initial public offering of Dynatrace and multiple follow-on public offering by stockholders of Dynatrace
    • Underwriters in the $90 million initial public offering of Graybug Vision
    • Underwriters in the $143.8 million initial public offering of Ikena Oncology
    • Underwriters in the $172.5 million initial public offering of Rhythm Pharmaceuticals

  • Debt Offerings

    • Analog Devices in multiple public offerings of senior notes
    • Apellis Pharmaceuticals in multiple private placements of $540 million of convertible notes and private exchanges of convertible notes for common stock
    • Karyopharm Therapeutics in its $150 million private placement of convertible notes
    • Medtronic in multiple public offerings of senior notes
    • MicroStrategy in multiple Rule 144A offerings of convertible notes
    • MKS Instruments in its $1.4 billion Rule 144A offering of convertible notes
    • National Securities Clearing Corporation in multiple Rule 144A offerings of senior notes
    • S&P Global in multiple public offerings of senior notes
    • TechTarget in its $360 million private placement of convertible notes

Recognition

  • Named a 2021 Top Rising Star by The Deal

Insights & News

View all of Craig's insights & news

Credentials

  • Education

    • JD, Catholic University of America, Columbus School of Law, 2008

    • BA, Economics and Political Science, Wake Forest University, 2003

  • Admissions

    • Massachusetts

    • New York

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel